Trial Profile
Switch From an NNRTI or PI-based Regimen to a RAltegravir-based Regimen in Virologically Suppressed HIV-infected Patients: Effects on Platelet Reactivity, Platelet-monocyte Aggregation and the Inflammatory anD Thrombotic State of Monocytes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Non-nucleoside reverse transcriptase inhibitors
- Indications Blood platelet disorders; HIV infections
- Focus Biomarker; Pharmacodynamics
- Acronyms RAPID
- 20 Aug 2018 Status changed from recruiting to completed, according to results published in the AIDS.
- 20 Aug 2018 Results published in the AIDS.
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections.